Start Your Journey To Wealth

It takes just a few minutes to register.

Your Money - Best Investment ISA - Large Portfolio 2024
Boring money - Best for Customer Service 2022
Broker Chooser - Best broker for funds 2022

SMITH & NEPHEW PLC ORD USD0.20

Symbol: SN.

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Login Open an account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date 27 Mar 2025
Pay Date 28 May 2025
Total Dividends - Year to Date28.58
Dividend Yield (%)2.5771

Historical Data & Ratios

Avg Volume Over 10 Days1.4540
Market Cap (M)9736.2620
Price/Earnings (PE)29.4008
Earnings Per Share37.72
Revenue Per Share4.8582
Return on Equity %7.8611

1 Month Performance Chart

One Month Chart

Broker View
Data shown is based on the past 75 days of broker views.

ActionBrokers

Strong Buy4

Buy4

Neutral9

Sell0

Strong Sell0
Brokers 4 4 9 0 0
Consensus

ConsensusBuy

Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.30% per annum (excluding Charles Stanley Multi Asset Funds and anycash held). The min fee is £60, the max is £600 per annum, plus SIPP administration fee (if applicable, only charged if < £30,000 held) – see here 		0.30%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included. This does not include any commission credits you may have available 		N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs 		N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

      Financial Summary

      BRIEF: For the fiscal year ended 31 December 2024, Smith & Nephew plc revenues increased 5% to $5.81B. Net income increased 57% to $412M. Revenues reflect Sports Medicine & ENT segment increase of 5% to $1.82B, Orthopaedics segment increase of 4% to $2.31B, Advanced Wound Management segment increase of 5% to $1.68B, United States of America segment increase of 5% to $3.12B, Other Established Markets segment increase of 12% to $1.27B.

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Revenue 5,810.00 5,549.00 5,215.00 5,212.00 4,560.00 5,138.00
      Gross profit 4,079.00 3,895.00 3,701.00 3,705.00 3,185.00 3,812.00
      Operating Profit/Loss 657.00 419.00 442.00 660.00 295.00 815.00
      Profit Before Tax 498.00 290.00 235.00 586.00 246.00 743.00
      Profit After Tax 412.00 263.00 223.00 524.00 448.00 600.00
      Equity Holders of Parent Company 412.00 263.00 223.00 524.00 448.00 600.00
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2024

      31/12/2023

      31/12/2022

      31/12/2021

      31/12/2020

      31/12/2019

      Total Non-Current Assets 5,933.00 5,957.00 6,110.00 6,496.00 6,348.00 6,080.00
      Total Current Assets 4,421.00 4,030.00 3,856.00 4,424.00 4,664.00 3,219.00
      Total Assets 10,354.00 9,987.00 9,966.00 10,920.00 11,012.00 9,299.00
      Total Liabilities 5,089.00 4,770.00 4,707.00 5,352.00 5,733.00 4,158.00
      Total Net Assets 5,265.00 5,217.00 5,259.00 5,568.00 5,279.00 5,141.00
      Shareholders Funds 5,265.00 5,217.00 5,259.00 5,568.00 5,279.00 5,141.00
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity 5,265.00 5,217.00 5,259.00 5,568.00 5,279.00 5,141.00

      Outlook

      Broker View
      Data shown is based on the past 75 days of broker views.

      ActionBrokers

      Strong Buy4

      Buy4

      Neutral9

      Sell0

      Strong Sell0
      Brokers 4 4 9 0 0
      Consensus

      ConsensusBuy

      Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

      © 2022 Refinitiv, an LSEG business. All rights reserved.

      Forecasts

      Year 2025 2026 2027
      Revenue £6,108.90mn £6,434.50mn £6,755.66mn
      Pre-tax-Profit £1,077.71mn £1,193.38mn £1,314.79mn
      EPS £0.76p £0.86p £0.90p
      EPS Growth -10.10% 13.54% 4.23%
      P/E 14 12.36 11.8
      PEG Ratio -1.39 0.91 2.79
      Dividend 29.34p 32.20p 35.35p
      Yield 0.00% 0.00% 0.00%

      Upgrades & Downgrades (Latest)

      DateBrokerRecommendationPriceOld TargetNew TargetChange
      14th Jan 2025JP Morgan CazenoveReiteration978p0p1180pOverweight
      5th Aug 2024Berenberg BankReiteration1167p0p14500pBuy
      16th Jul 2024Berenberg BankReiteration1062p0p1450pHold
      7th May 2024RBC Capital MarketsReiteration998p0p1500pOutperform
      3rd May 2024JefferiesReiteration997p0p1250pBuy
      2nd May 2024JP Morgan CazenoveReiteration986p1300p1381pOverweight
      2nd May 2024Berenberg BankReiteration986p0p1450pBuy
      18th Apr 2024JP Morgan CazenoveReiteration967p0p1300pOverweight
      5th Apr 2024RBC Capital MarketsReiteration975p0p1500pOutperform
      3rd Apr 2024JP Morgan CazenoveReiteration976p0p1300pOverweight

      Time & Sales

      All prices are in GBX and times are in GMT. Last 20 trades shown. Trade type is estimated and should be treated as indicative only.

      Date Time Price Volume Type
      7 Jul 2025 16:35 1,109 2,895 Buy
      7 Jul 2025 16:35 1,109 136 Buy
      7 Jul 2025 16:35 1,109 334,812 Buy
      7 Jul 2025 16:35 1,109 5,595 Buy
      7 Jul 2025 16:35 1,109 16,738 Buy
      7 Jul 2025 16:29 1,110 215 Sell
      7 Jul 2025 16:29 1,110 316 Sell
      7 Jul 2025 16:29 1,110 243 Sell
      7 Jul 2025 16:29 1,110 65 Sell
      7 Jul 2025 16:29 1,110 58 Sell
      7 Jul 2025 16:29 1,110 329 Sell
      7 Jul 2025 16:29 1,111 235 Buy
      7 Jul 2025 16:29 1,111 67 Buy
      7 Jul 2025 16:29 1,111 1,200 Buy
      7 Jul 2025 16:29 1,111 500 Buy
      7 Jul 2025 16:29 1,111 500 Buy
      7 Jul 2025 16:29 1,110.5 1,092 Sell
      7 Jul 2025 16:29 1,110.5 555 Sell
      7 Jul 2025 16:29 1,110.5 341 Sell
      7 Jul 2025 16:29 1,110 69 Sell

      Selected data supplied by Thomson Reuters ©  View restrictions.

      Investment involves risk. You may get back less than invested.